GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (OTCPK:ADXS) » Definitions » ROE %

ADXS (Ayala Pharmaceuticals) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ayala Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Ayala Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was $-98.69 Mil. Ayala Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-15.33 Mil. Therefore, Ayala Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Ayala Pharmaceuticals's ROE % or its related term are showing as below:

ADXS's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.68
* Ranked among companies with meaningful ROE % only.

Ayala Pharmaceuticals ROE % Historical Data

The historical data trend for Ayala Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ayala Pharmaceuticals ROE % Chart

Ayala Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial - - -110.96 -229.97 -

Ayala Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -319.25 -1,106.74 - - -

Competitive Comparison of Ayala Pharmaceuticals's ROE %

For the Biotechnology subindustry, Ayala Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ayala Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Ayala Pharmaceuticals's ROE % falls into.



Ayala Pharmaceuticals ROE % Calculation

Ayala Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-48.072/( (-1.099+-24.417)/ 2 )
=-48.072/-12.758
=N/A %

Ayala Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-98.692/( (-6.241+-24.417)/ 2 )
=-98.692/-15.329
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Ayala Pharmaceuticals  (OTCPK:ADXS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-98.692/-15.329
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-98.692 / 0)*(0 / 11.78)*(11.78 / -15.329)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-98.692/-15.329
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-98.692 / -98.28) * (-98.28 / -35.12) * (-35.12 / 0) * (0 / 11.78) * (11.78 / -15.329)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0042 * 2.7984 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Ayala Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Ayala Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ayala Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 08852
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
Executives
Yair Chaim Schindel other: shareholder of 10% holder YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
Roni Mamluk director, officer: CEO CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
Gary B. Gordon officer: Chief Medical Officer C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104
David Sidransky director JOHNS HOPKINS UNIVERSITY, 720 RUTLAND AVENUE, BALTIMORE MD 21205
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Harel Insurance Co Ltd 10 percent owner ABBA HILLEL 3, RAMAT GAN L3 5211802
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Maimon Yossi officer: CFO C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL L3 20100
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Harel Insurance Investments & Financial Services Ltd. 10 percent owner HAREL HOUSE, 3 ABBA HILLEL ST., RAMAT GAN L3 52118
Todd Sone director C/O AYALA PHARMACEUTICALS, INC., OPPENHEIMER 4, REHOVOT L3 7670104